Currently Avodart is still awaiting approval by the FDA for the treatment of male pattern baldness (MPB). At the time of writing, Propecia is the only oral medication approved by the FDA for MPB. It is fair to say (without putting a percentage to it) that Avodart is reported (by physicians who specialize in its usage) to work better on patients who are not getting good responses to Propecia.

Finasteride was originally distributed by pharmaceutical giant Merck. in a 5 mg dose under the brand name Proscar for treatment of Benign Prostatic Hyperplasia (BPH).  In 1997, Merck was granted FDA approval for the use of finasteride as a hair loss treatment in a much smaller 1 mg version dose. This Finasteride drug for use as a hair loss treatment was named Propecia.  This was a landmark event because it was the first true “baldness pill” the world had ever known. The discovery of positive effects in the area of hair loss was actually accidental; the benefits were reported by sufferers of Benign Prostatic Hyperplasia. These findings prompted Merck to conduct qualitative double-blind investigations into the effectiveness of the drug, the rest of which is history.

Following on from the development of Finasteride, the hair-loss market has continued to move, since the FDA approval of Propecia another DHT inhibiting drug with great potential for inhibiting hair loss has come on the scene.  This drug is called Dutasteride, marketed under the brand name of Avodart (also available as Generic Avodart or “Dutas”). Like Finasteride, Dutasteride / Avodart is a 5AR inhibitor, however unlike Finasteride, Dutasteride inhibits both Type I AR and Type II AR meaning it is far greater scope for blocking the alpha 5 enzyme – which is directly responsible for hair loss.  Dutasteride also has a much longer half-life than Propecia, this means that the drug is present within the body for far longer – another reason perhaps that initial trials have shown a greatly increased efficiency.

Also like Proscar, Avodart and Generic Avodart are available for prescription for treatment of BPH and have FDA approval for that application. 

Since Avodart is a dual 5AR inhibitor and is much stronger than Propecia, it is generally accepted that it is possible that it can be a more effective treatment for male pattern baldness.

We recommend Generic Avodart in extreme cases of male pattern baldness, or in rare cases where Propecia is not proven to be effective / produced the desired effects.

If someone were to tell you that you had an 83% chance of keeping all the hair you currently have by taking a pill every day, would you do it? With Generic Propecia, it's not only a possibility, it's a reality. For younger men looking to keep a full head of hair, and the rest of us who just want to keep our hair loss from getting any worse, this treatment is key. Find out why Propecia is the leader of the pack in clinically-proven hair loss treatments, and why you should include it in your regimen.

Propecia, or Finasteride, is a once-daily pill proven to help reduce DHT, dihydrotestosterone. DHT is a substance in the body that has been strongly linked to thinning hair and is one of the main causes of male pattern hair loss. This chemical shrinks hair follicles until they are no longer visible on the scalp. Propecia successfully blocks DHT, reducing further hair loss and regrowing hair. It has only been approved to treat hair on the vertex—top of the head—and the anterior mid-scalp area—middle front of the head—. After a five-year clinical study, nine out of ten men who took Propecia had visible results of either hair regrowth (48%) or no further hair loss (42%).

Propecia should be taken for at least 3 months before results start to show. Men who took the hair loss pill reported a reduction in the size of their bald spots, a slowdown in hair loss and an overall improvement in their hair appearance.

Propecia is an offshoot of another medication called Proscar, which has been widely used since 1992. This 5mg tablet containing the active ingredient "Finasteride" was used to reduce the adverse effects of DHT on the system. As hair loss is primarily linked to the effects of DHT, it was reasoned that Finasteride would help stop or reverse the process. FDA trials on 1,500 men yielded shocking results. Nearly 83% of men who continued treatment for 2 years either saw a complete stop of hair loss, an increase in hair growth, or both. Results were confirmed by actual hair counts and nearly 80% of men were categorized by visual assessments that their appearance had improved. A 1mg version called Propecia was released in 1998. To date, Propecia has the longest, most successful run of any treatment to have undergone FDA trials. We have members here on HairlossTalk who have successfully maintained their hair using Propecia (coupled with Nizoral shampoo) for nearly 10 years.
What is Generic Finasteride, or Finpecia?
 

Generic Finasteride, brand name "Finpecia" contains the same exact active ingredients as Propecia, and is the international equivalent of Propecia. Yes, Generic Finasteride is a legitimate 1mg tablet of Finasteride, just like Propecia.

SUMMARY

•  No long-term ( > 2 years) clinical trials have directly compared the efficacy and safeaty of dutasteride and finasteride. Withoug such trials, conclusions regarding the relative efficacy and safety of one agent over the other may not be made.

•  Both dutasteride and finasteride are 4-azasteriod competitive inhibitors of 5 alpha-reductase, the enzyme responsible for converting testosterone to dihydrotestosterone (DHT), which is the more potent androgen in the prostate. Dutasteride inhibits both types of isoenzymes (type 1 and 2) of 5 alpha-reductase while finasteride selectivelyinhibits the type 2 isoenzyme. both agents decrease epithelial cell size and funciton within the prostate in patients with benign prostatic hyperplasia (BPH) through an increased rate of apoptosis.

•  In clinical trials, chronic dutasteride thereapy reduces serum DHT by 93 to 94% while finasteride reduces serum DHT by approximately 70%. Reductions in intraprostatic DHT concentrations have not been directly compared between the two drugs. most trials assessing intraprostatic DHT reductions utilized doses higher than those used for the treatment of BPH.

•  In non-comparative trials, chronic therapy with either agent reduced prostate volume significantly in patients with BPH. Both agents have been shown to arrest the disease process in patients with BPH and are indicated to improve symptoms and to reduce the risk of acute urinary retention (AUR) and BPH-related surgery. Both agents increase serum testosterone concentrations by 10 to 20%. Neither drug affects bone mineral density nor serum lipid profiles.

•  The pharmacokinetics of ditasteride are somewhat different than that of finasteride. The major differences include a larger volume of distribution for dutasteide, resulting in a longer elimination half-life. both agents are metabolized by the cytochrome (CYP) P450 3A4 system to active metabolites, although dutasteride is also partly metabolized via the CYP 3A5 pathway, based on in vitro studies. No clinically meaningful drug interactions have been observed with either drug.

•  For both agents, the most frequently reported drug-related adverse events were related to sexual funciton. These included impotence, decreased libido, decreased volume of ejaculation and ejaculation disorders, and breast tenderness and/or enlargement. The onset of drug-related sexual adverse events appears to diminish with time for both drugs.

•  One clinical trial directly comparing dutasteride with finasteride was conducted in Europe. The primary endpoint was to evaluate the effect of either drug on prostate volume after 12 months of double-blind therapy. For the intent-to treat population, prostate volume was reduced from basleine in both the dutasteride and finasteride groups at month 12. dutasteide produced m\numerically but not statistically significant greater improvements in symptoms and urinary flow rates compared with finasteride. Although fewer drug-related sexual adverse events occurred in patients receiving dutasteride than finasteride, there were no significant differneces between the two drugs (17% in the dutasteride group compared with 20% in finasteride-treated patients). Whether similar results would occur with a longer clinical trial ( > 2 years) is not known.

•  A brief 3-month prospective and consecutive study was conducted to evaluate the onset of symptom relief with Avodart versus Proscar (finasteride, Merck & Co.) One hundred twenty men with symptomatic benign prostate hyperplasia (BPH) were treated with Avodart, followed by an additional 120 men treated consecutively with Proscar for 3 months in each trial. Among patients who recieved Avodart, there were significantly greater reductions in AUA-SO scores compared with Proscar in the first 3 months ( P <0.0016). Conclusion drawn from this study must be considered carefully in light of the study design.
 
 
 
Some information contained in thes rsponse may be outside the approved prescrbing information for Avodart?. No long-term clinical trials have compared the efficacy and safety of Avodart and Proscar in the U.S. In the absence of such trials, a brief reiew of key areas from the literature and each product's prescribing information is provided for your review and may help differeetiate the products. This response is not intended to ofer recommendations for administering Avodart in a manner inconsistnet with its approved labeling. In order for GlaxoSmithKline to monitor the safety of Avodart, we encourage healthcare professionals to report adverse events or sespected overdoses to the company at 888-825-5249. Please consult the Prescriging Information for Avodart.
 
 
INTRODUCTION
No long-term ( > 2 years) clinical trials have directly compared the efficacy and safety of dutasteride and finasteride. Without such trials, conclusitons regarding the relative efficacy and safety of one agent over the other may not be made. This letter describes differences and similarities between dutasteride and finasteride based on pharacologic, pharmacokinetic and pharmacodynamic effects, as well as a summary of clinical trial information and adverse events reported from these trials. One short-term direct comparative trial conducted in Europe is describedin which patients with benign prostatic hyperplasia (BPH) received either dutasteride or finasteride for 1 year of treatment.
 
COMPARISON OF PHARMACOLOGY
5alpha-Reductase Isoenzyme Inhibition
Both dutasteide and finasteride are 4-azasteroid inhibitors of 5 a -reductase , the enzyme responsible for converting testosterone to dihydrotestosterone (DHT) in the prostate. DHT is the primary androgen int the prostate and has a major role in the development and progression of benign prostatic hyperplasia (BPH) and other prostate diseases (1,2,3,4) as well as androgenetic alopecia (5,6).

Two isoenzymes of 5 a -reductase exist (type 1 and type 2). Type 2 is the dominant isoenzyme in genital tissues including the prostate, but is also present in the skin and liver. Type 1 5 a -reductase is also found in the skin, liver and prostate, and is the dominant form in sebaceous glands. (1,2,4). Although early studies did not observe the presence of type 1 isoenzyme in the prostate (5), more recent studies using more sensitive assays indicate that both type 1 and type 2 mRNA protein and enzymatic activity are present in prostate tissues. (7,8,9,10,11,12). In one of these studies, mRNA expression for both types 1 and 2 was slightly but significantly increased in BPH tissue when compared to the levels observed in normal prostate tissue. In cancer samples, type 1 mRNA expression was higher than in normal and hyperplastic prostate (11,12) but the level of type 2 mRNA was not statistically different from thatobserved in the normal prostate (11). In th!e liver, type 2 mRNA was expressed at levels similar to those measured in BPH tissue while type 1 mRNA expression was ten times higher. (11)

Generic Finasteride is a competitive inhibitor of 5 a -reductase that selectively inhibits the type 2 isoenzyme, with which it forms a stable enzyme complex. this selective activity is attributed to a much lower affinity for the type 1 isoenzyme, and thus a slow rate of type 1 isoenzyme inhibition. In contrast, dutasteride is a competitive inhibitor of both forms of the enzyme, with 45-fold greater potency than finasteride against type 1 and type 2 isoenzymes at clinically used doses. this dual inhibition may potentially be beneficial in prostatic diseased that depend on androgens, since both isoenzymes are up-regulated in BPH while only the type 1 isoenzyme is up-regulated in prostate cancer, as noted above (2,1). However, whether clinical differences in the treatment of BPH occur between selective versus dual inhibitors of 5 a -reductase is not known.

Turnover from the enzyme complex is extremely slow for both agents. Neither agent possesses anti-gonadotrophic or anit-androgenec properties, and they do not bind to the androgen receptor. (1,14,15).

during the fi4rst several minths of therapy in patients with BPH, both dutrasteride and finasteride cause progressive decreases in epithelial cell size and function within the prostate, through and increased rate of apoptosis, which histologically is manifested by ductal atrophy (1,2,16,17).

Serum DHT Reduction

After chronic administration of doses recommended for the treatment of bPH, serum DHT suppression is significantly greater with dutasteride (0.5 mg daily) than that observed with finasteide (5mg daily). In clinical trials, chronic therapy with dutaseride 0.5mg daily for up to 2 years in patients with BPH resulted in median reductions in serum DHT concentrations of 94% and 93% after 1and 2 years, respectively (14). In contrast, long-term therapy with finasteride 5 mg daily for up to 4 years in patients with BPH suppressed serum DHT concentrations by appr5oximately 70% (15).

Treatment of BPH patients with either agent produces dose-dependent, rapid reductions in serum DHT concentrations (14,15). After 1 and 2 weeks of dutasteride 0.5 mg daily, median serum DHT concentrations were reduced by 85% and 90% respectively (14). With repeated daily dosing, serum DHT concentration reductions are observed within 8 hours after finasteride administration (15).

In addition to the above non-comparative data, a Phase II dose-ranging rial of dutasteride in patients with BPH (n=392) and an enlarged prostate ( > 30 cc as measured by transrectal ultrasound) directly compared various doses of dutasteide with finasteide 5 mg daily in a double-blind, placebo controlled trial. An additional follow-up phase for 4 months after patients had ended the double blind phase was included. The study was not powered to detect clinical differneces in symptoms between dutasteride and finasteride. The mean reduction in baseline DHTconcentration in patients recieving 0.5mg dutasteride daily was greater and less variable than in patients receiveing finasteride 5mg daily (94.7 + 3.3% and 70.8 + 18.3%, respectively, p<0.001). (18)

During the follow-up period (after study medication was stopped), mean DHT concentrations retruned to within 20% of their baseline values at 16 weeks in patients receiving dutasteride, compared with 4 weeks in those receiving finasteride.(18)

Intraprostatic DHT Reduction

Intraprostatic reductions in DHT have been evaluated in Phase II clinical trial in BPH patients after receiving 5mg dutasteride daily, a higher dose than the dosage used for the treatment of BPH. Patients were randomized to receive treatment with dutasteride 5mg daily or placebo for up to 12 weeks prior to transurethral resection of the prostate (TRUP). Mean DHT concentrations in prostatic tissue were significantly lower in the dutasteride group. Intraprostatic concentrations were 784 pg/g in the dutasteride group (N=24) compared with 5793 pg/g in the placebo group (n=19, p<0.001). Serum DHT concentration was reduced by a median value of 97.1%. (16)

In another Phase Ii clinical trial, patients weith clinically staged T1, T2 prostate cancer were randomized to receive treatment with high doses of dutasteride or placebo for 6-10 weeks prior to undergoing planned radical prostatectomy. Dutasteride was administered as a loading dose of 10mg daily for the initial 7 days followed by 5mg daily thereafter. Intraprostatic DHT values obtained in patients receiveing dutasteride were 2.9% of those obtained in patients receiving placebo, representing a 97.1% reduction in ccomparison with the placebo group. Serum DHT concentrations were reduced by 96.4% from baseline in patients receibing dutasteride without significantly increasing serum testosterone concentrations. The ratio of serum DHT to testosterone concentrations was also significantly less in subjects receiving dutasteride compared to placebo (>90% reduction with dutasteride compared to baseline). (19)

In a phase Ii trial, 69 patients with BPH were treated with finasteride 1 to 100 mg daily (one-fifth to 200 times the normal daily dosage) for 7-10 days prior to prostatectomy. Intraprostatic DHT concentrations for the entire range of dosed sdministered were approximately 80 lower than those in patients receiving placebo (15,20). Of the 69 patients, 12 patients recieved 5mg daily, the dosage used for the treatment of BPH. In these 12 patients, the exact values for intraprostatic DHT were not described. All dosage levels with in the finasteride griop resulted in statistically significant differences compared to values obtained in the placebo group, but not different from each other. However, the authors stated that the 100mg daily dose was more effective than the 1 and 5mg daily doses. (20) The study firation of 7 days was insufficient time for patients to have achieved steady-state dosing of the frug, since the time to reach steady-state dosing with finasteride is >ulnone 17 days (21).

In another trial, 27 men with symptomatic BPH were treated with placebo, 1mg finasteride daily or 5mg finasteride daily for 6-8 weeks prior to planned transurethral resection of the prostate (TURP). Serum and intraprostatic DHT concentrations correlated well. After 1 and 5mg daily dosing, serum DHT concentrations were reduced by 66% and 70% respectively. Intraprostatic DHT concentrations were reduced by approximately 80% and 90% respectively, in patients receiving 1 and 5 mg daily dosing compared to the mean value obtained at surgery in the placebo group. (22)

In another trial, 27 men with symptomatic BPH were treated with placebo, 1mg finasteride daily or 5mg finasteride daily for 6-8 weeks prior to planned transurethral resection of the prostate (TURP). Serum and intraprostatic DHT concentrations correlated well. After 1 and 5mg daily dosing, serum DHT concentrations were reduced by 66% and 70% respectively. Intraprostatic DHT concentrations were reduced by approximately 80% and 90% respectively, in patients receiving 1 and 5 mg daily dosing compared to the mean value obtained at surgery in the placebo group. (22)

The remaining DHT in the prostate after finasteride therapy is likely to be the result of type 1 5 a -reductase, either originating from the 30% of DHT remaining in the serum of men receiving finasteride or from intraprostatic type 1 5 a -reductase (1). The contribution of remaining DHT in the serum and the small amount of type 1 in the prostate may play a role in maintaining prostatic enlargement (2). Inhibition of both type 1 and type 2 5 a -reductase may potentially offer advantages in the treatment of BPH and other diseases that depend on DHT compared with selective inhibition of the type 2 isoenzyme alone (1,2,3,5). However, long-term direct comparative trials in patients with BPH are necessary to determine whether clinically significant differneces exist among dual and single inhibitors of the enzyme (dutasteride and finasteride, respectively).

The trials discussed above have not evaluated intraprostatic DHT concentration reductions after steady-state dosing had been achieved for either dutasteride or finasteride, and the doses evaluated were significantly higher than those approved for the treatment of BPH in both dutasteride trials and one of the finasteide trials. Intraprostaic concentration reductions achieved with doses approved for the treatment of BPH are not yet available for dutasteride.

Effect on Serum Testorsterone, Bone Density and Lipid Metabolism

Both dutasteride and finasteride increase median circulating testosterone concentration by 10-20% from baseline values, but concentrations remained within normal physiologic limits. In addition, neither agent causes significant changes in bone density or lipid metabolism. (14,15)

Effect on Serum PSA Values

Both agents reduce serum PSA values to similar extents. Dutasteride reduces total serum PSA concentration by approximately 40% following 3 months of treatment and approximately 50% following 6,12,and 24 months of treatment (14). This decrease is predictable over the entire range of PSA values, although it may vary in individual patients. However, since the ratio of free to total PSA is not significantly altered (23), PSA may still be used as a screening tool for the detection of prostate cancer. To interpret an isolated PSA value in a man treated with either agent for 6 months or more, the PSA value should be doubled for comparison with normal values in untreated men.(14,15)
 

The chemical name of Avodart is dutasteride. It belongs to the category of drugs known as 5- alpha reductase inhibitor. It prevents the conversion of testosterone into dihydrotestosterone in the body. Dihydrotesteosterone causes benign prostatic hyperplasia. Avodart is used for the treatment of benign prostatic hyperplasia in men with an enlarged prostate. It reduces the need of prostate surgery as this medication has the ability to improve urinary flow. Sometimes this is also used to treat male pattern baldness. Avodart is also prescribed along with another medicine called tamsulosin (Flomax).

Avodart is suggested not to be used by women and children. This is prescribed solely for men. Dutasteride may be absorbed through the skin. As a result women and children should not handle it. If pregnant women are exposed to this tablet, it can lead to birth defects in the child.

The medication has t be taken as a whole. If an Avodart tablet is crushed, chewed or broken, it will irritate the lips, mouth and throat while swallowing. This drug can be taken with or without food. Doctors always ask the patients to drink enough water to avoid dehydration and other side effects. Regular checking of prostate and prostate specific antigen (PSA) will help detect prostate cancer and to know about the body's response to the medicine. It will take about 6 months for the drug to show positive results.

Certain people may be allergic to Avodart or any of its ingredients. In such cases it is advised not to use this medicine. Hives; breathing trouble; swelling on the face, lips, tongue and throat are the common allergic reactions caused by the medication. These require urgent medical attention. Less serious side effects include poor sex drive, decrease release of semen during sex, impotence, breast tenderness and enlargement. Many of the troubles can be avoided with the strict adherence to the doctor's advice.

Generic Avodart is a well known drug and at the same time it is widely considered as the best option for most of the strange diseases that you might come along. It is always advised to buy these drugs at Online Pharmacy, as you can save a lot of time and money. You can click here to buy Generic Avodart.

Optimum heath is important for a healthy head of hair. Just like any living and growing part of the body, the hair needs to receive proper nutrition. A highly balanced diet, coupled with vitamin and mineral supplementation and exercises are vital to take care of healthy hair. Without the proper nutritional routine, the hair follicle is sure to suffer.

With today's research and new discoveries, there is a lot of confidence within the field of hair loss and restoration. Since hair is definitely a important portion of one's appearance and self-esteem, more importance has been put on the study for more solutions. The probabilities are good that there is a solution to most situations now or in the near future.

Hair Loss causes

95 % of folks that suffer the loss of hair have either Male Pattern Baldness or androgenetic alopecia. An elevated amount of dihydrotestosterone ("DHT") in the body brings about these ailments, which is a result of testosterone levels. By means of recent investigation, the outlook for both of these conditions indicates great hope and promise.

Androgenetic alopecia

This ailment is found mostly in Western civilization and nations which have adopted Western civilization's way. Because the diet of Eastern countries lacks the consumption of red meat and greasy foods, this leads someone to think that the dietary plan can have an impact on hair loss and disease. Dietary changes may not only affect temporary loss of hair but could possibly affect androgenetic alopecia as well.

DHT

The means by which this occurs would be that the DHT attaches to your follicles and gradually strangles their ability for taking up nutrients necessary to hair health. Like other organs within our body our hair needs a sufficient supply of nutrients and, like our other organs, if these are unavailable it will become unwell. It'll shrivel and die.

Over-the-counter treatments like Propecia, Rogaine and Rogaine for Women and modern surgical treatments have given people other available choices to take into account, instead of just accepting balding or wearing wigs or hairpieces. Studies have opened the threshold to more natural solutions like horsetail, rosemary, nettles and saw palmetto.

Remember, the restoration of hair regrowth just isn't an overnight progression. The method takes time regardless of the method chosen. Show patience, even the best products will require no less than 3 months to show signs of improvement. Don't give up, lots of people have had positive results at stopping hair loss.

Generic Avodart is the brand name for the drug Dutasteride commonly used in the treatment of benign prostate hyperplasia. This is used to treat the enlargement of the prostate gland. Avodart prevents conversion of testosterone to dihydrotestosterone, which is a compound believed to result in benign prostate hyperplasia. Use of Avodart makes urine flow better and reduces the chance of surgical intervention for the prostate gland enlargement. At times Avodart is used along with another drug Flomax, about which the treating physician you give you the information you need and you should strictly follow the instruction about the doses of each of them.

You should not chew or crush the capsule while or before consuming it, as the drug can cause irritation in your mouth. This drug is not used in women and children. This drug can result in defective birth if used during pregnancy. Precaution should be taken while using Avodart. A pregnant woman or who is expected to be pregnant should not come in contact with this drug and if accidentally this happens due to a leaky capsule, the area should be immediately washed, as this medicine is absorbed through skin. A person who is on medication of Avodart should avoid donating blood for at least within six month of administration of the drug.

Avodart might result in side effects or allergic reaction resulting in breathing difficulty, swelling of skin, face lips or throat and this should be immediately reported to the treating physician for immediate measures .Some other mild problems of decreased sexual drive, decreased amount of semen, compromised erection, tenderness or enlargement of breast. Incase you have had an allergic reaction to this drug earlier you must inform this to your physician.

There may be some drug reaction of Generic Avodart with other drugs; hence if you are already taking some drugs, you must inform your physician so that adverse reactions are avoided.

Avodart is a well known drug and at the same time it is widely considered as the best option for most of the strange diseases that you might come along. You can click here to Buy Generic Avodart.

Propecia, active ingredient finasteride, is a prescription treatment for male pattern hair loss. It's a tablet meant for daily use and needs to be taken over the long term if you want to experience benefits in terms of decreased hair loss and hair regrowth.

Results from clinical trials

The effectiveness of this male pattern baldness has been confirmed through a 5-year clinical trial. The results of the trials were as follows:

Visible results were seen in nine out of ten men who were given Propecia. These results were in the form of a complete stoppage of hair loss; regrowth of hair was another effective result. In order to ensure that there were no discrepancies in the findings and that the findings were trustworthy, an independent panel of leading dermatologists was asked to assess the photographs.
In terms of hair count, 2 out of every 3 men in the study who were given Propecia experienced good results. Also, it was seen that, men who were not given Propecia did not show any improvement in hair re-growth.
As compared to men who took a placebo, 77% of the men showed a marked improvement which was rated by doctors.
A large percentage of men who were a part of the trial reported a reduction in their bald spot and the fact that their hair loss reduced.

Important safety information

The drug is well tolerated by most men, but you also need to be aware of some important safety information about this drug. This will help you make better use of it and also understand the kind of problems, if any, that you might face when you take this drug.

Most men suffer from no side effects of taking this medication; but those who do, can suffer from allergic reactions such as swelling of the face and lips, itching, rash and hives. Other side effects can include ejaculatory problems, testicular pain and breast tenderness and enlargement. If you experience some side effects after taking this medication, get in touch with your doctor to ensure that such side effects are normal and will go away after sometime. There is a chance that such side effects might become bothersome; in this case a doctor might ask you to avoid taking this medication.

This drug has been created for use in men only and should not be used by women and children. Pregnant women are advised not to even handle this medication in its crushed or broken form, as finasteride might cause abnormalities in your unborn baby's sex organs, if it's a male child. If you have come in contact with Propecia, it's important that you consult your doctor immediately.

ED and Propecia

There is an off chance that the use of Propecia will lead to erection problems. This problem is experienced by a very limited number of men and occurs very rarely. If you have started facing erection problems after beginning treatment with this medication, there is a chance that Propecia is the reason behind your condition. But, it's advisable that you take your doctors opinion on the matter. There is always the chance that your condition has cropped up because of some underlying health condition or some physical or psychological causes. So, blaming Propecia blindly won't do you any good. You need to know the right cause behind your erectile dysfunction. This will help you zero in on an effective treatment option for it.

You can Buy Cheap Propecia at the lowest prices around from GotHair.

Restoring the hair lost due to hereditary factors is the dream of many hair loss sufferers. Until not too long ago, the only effective and authentic-looking methods of reversing hair loss were non-surgical cover-ups. It was only with the advent of follicular unit transplantation and the discovery of the true cause of baldness - the harmful effects of dihydrotestosterone (DHT) on our hair follicles - that the hair-loss sufferer’s chances of reversing hair loss naturally have greatly improved.

The three best weapons in the fight against baldness today are the two FDA-approved medicinal drugs – finasteride (Propecia) and minoxidil (Rogaine) and hair surgery, the follicular unit transplantation and, especially, the follicular unit extraction technique. However, no ultimate cure exists yet as each of the three aforementioned hair restoration methods has its limitations. Minoxidil and finasteride work well only in the vertex area of the scalp, and finasteride cannot be used by women. Hair transplant surgery is suitable only for people who have sufficient hair density in the donor area, and many women, who typically suffer from diffuse thinning, do not make good candidates for hair transplantation.

Therefore, scientists around the world are relentlessly searching for new approaches to treating hair loss. There are presently several promising medications and new techniques under development listed below but progress seems to have slowed down a bit due to the global financial crisis, as some projects are finding it increasingly difficult to raise financing to further their research.

The greatest progress has been achieved on dutasteride. Dutasteride is an antiandrogen, in its chemical structure and mode of action it is similar to finasteride. It is used to treat benign prostatic hyperplasia and since it is a dual 5-alpha reductase inhibitor, it should be a more potent DHT blocker than finasteride. Therefore, it is thought to be more effective in treating hair loss, especially in the frontal area of the scalp. Dutasteride completed Phase III clinical testing this year and the study results are expected to be published soon.

NEOSH101 was originally developed by the US medical research firm Neosil and was until recently undergoing phase IIb clinical testing. At the end of 2008, Neosil was taken over by Peplin, Inc., a development stage specialty pharmaceuticals company and since then no information on the further progress of the clinical trials has been released. In previous clinical trials, NEOSH101 was shown to be a more powerful and faster-acting, hair growth stimulant than minoxidil and it only needs applying once daily. Though significantly improving the current hair-loss treatment options, NEOSH101 is not going to become the ultimate cure for baldness. The clinical trials seem to be advancing slower than most hair-loss sufferers would like and, hence, do not hold your breath waiting for it to hit the market anytime soon.

Another promising area of development is the telomerase research. Telomerase is an enzyme that is able to put natural caps on telomeres and thus protect them from shortening. Telomerase thereby maintains the genomic integrity. Shortened telomeres are associated with premature aging processes. However, the uncontrolled activation of telomerase can cause cancer. Cancer research is the main focus of the telomerase studies but scientists are also looking for other applications, such as anti-aging drugs and drugs against baldness and premature grey hair. Telomerase research could really change the world of medicine but its commercial application might be a good 15 years away.

Hair multiplication, often called hair regeneration or hair cloning, is the next hopeful treatment option being developed. This technique involves extracting hair follicles from the back of the patient's scalp, culturing and multiplying them and injecting the newly-grown hair cells into the bald scalp area. The UK healthcare firm Intercytex appears to be the frontrunner in hair multiplication research. Intercytex has already completed phase II clinical study of ICX-TRC (a suspension of a patient's own dermal papilla cells). The main benefit of hair multiplication would be solving the shortage of donor hair that is the main limiting factor in hair transplant surgery. However, Intercytex is currently facing financial difficulties and after failing to find an investor, it will have to continue operating on its own. Aderans, the main competitor of Intercytex, has also recently launched a Phase II clinical study on cell-based hair regeneration for men and women.

Generating new hair follicles in hair-free skin wounds is an entirely new approach to regrowing hair. It was discovered accidentally when wounded skin in mice started producing new hair. This technology is currently being developed by the US medical device company, Follica, which has licensed this technology from the University of Pennsylvania. Though this method may sound a bit weird, it is said to only use common instruments and drugs that have already been medically approved and thus it might not take too long for it to become commercially available.

This list of the undergoing R&D projects in the field of hair-loss research includes the most promising lines of development but it is not exhaustive. However, none of the new therapies, with the exception of generic dutasteride’s approval for treating hair loss, is expected to hit the market before 2013 and the immediate future of hair restoration lies in improving the surgical techniques, increasing the yields of the follicular unit extraction method and making it more affordable to a larger portion of the population.

Male pattern hair loss on the vertex as well as the anterior mid-scalp area is a common problem now and men are using a variety of options to reduce the impact of this problem. However, they get the results but not so good as they wish. Keeping the same problem of numerous male in mind, one of the leading companies names Merck & Co has come up with an idea of formulating a medication that not only prevent hair loss, but also help in the re-growth of the hair. The medication is gaining popularity by the name of Propecia. It is a fact that Propecia, an FDA approved medication contains the key ingredients of Finasteride that helps in prevent the hair loss on the vertex and the anterior mid-scalp area in the male. The medication is not prescribed to women.

Because of successful and effective results, the medication has gained world recognition within a very short span of time. Today, generic Propecia has also formulated by using the same active ingredients used in the formulation of branded Propecia. Interestingly, generic Propecia is available at the prices one can afford easily. In other words, one can save a good amount of money. When it comes to buy generic or branded Propecia, it is extremely simple now with the advent of online pharmacy stores. with an aim of making online purchasing simple and hassle free, these stores also offer you flexible payment mode through all the legal money transfer processes.

No doubt, Generic Propecia is known for successful and efficient results, but possibility of some mild to moderate side effects cannot be ignored. Talking about the side effects, then some common side effects like headache, less desire of sex, difficulty in achieving erection, nausea and some others may occur. However, these side effects are common and last for a very short time. In case you feel the impact of any side effect for some more time, you are advised to stop using the medication and consult your doctor as soon as possible. Apart from this, the medication should be used only doctors' prescription and taken as per their guidelines. You are also advised to consult your doctor and also disclose your previous or current medical records. By doing so, you can get good results within the appointed time.

Propecia is a prescription medication that is used of the treatment of male pattern hair loss. An important fact to note is that it is prescribed for the treatment of only specific types of male pattern hair loss.

About Propecia

Generic Propecia, active ingredient finasteride, is used for the treatment of male pattern hair loss and is marketed by Merck. The action of Propecia targets the dihydrotestosterone, which is considered to be one of the most important causes of hair loss. It's a clinically studied prescription drug and has demonstrated highly visible results. Propecia is specifically developed for the treatment of mild to moderate cases of male pattern hair loss. This is the hair loss that occurs at the top of the head and also the middle front of the head. Propecia is a prescription medication that should be used by men and not by either women or children.

Effectiveness of Propecia

Clinical studies have proven that there is a significant reduction in the levels of DHT through the action of Propecia. The action of finasteride prevents the development of dihydrotestosterone (DHT) in your scalp. When the levels of DHT are reduced, it's seen that there is a considerable reduction in the shrinkage that affects hair follicles. DHT is a substance in the body that causes the shrinking of hair follicles. They keep shrinking until they can no longer produce visible hair. According to scientists, it is the family history of the person and DHT that are the prime drivers of hair loss. Propecia focuses on DHT and is found to be very effective. Propecia has been found effective in up to 80% of cases. It can not only help in stopping further hair loss but also lead to hair growth.

Results with Propecia - Time frame

It's important to understand that hair loss differs from person to person and hence the results of Propecia will not be the same for everybody. Also, you need to stick to it, for it to be effective. Many men have noticed a difference within 3 months of having started hair loss treatment with Propecia. Typically, it will take around 6 months for Propecia to start taking effect. To make sure that you do see results with Propecia it's important that you stick to it for 12 months. Results will be there for everybody to see.

Propecia tips and limitation

Don't use Propecia if you are allergic to any of its ingredients
It can be prescribed to maintain existing hair, before carrying out hair restoration procedures
Consult your doctor before using Propecia
Be aware of its side effects so that you can optimize the use of this medication.
The prescription pill needs to be taken daily to experience the best results.

The only limitation associated with Propecia is that it does not restore the hair loss that affects the frontal area of your scalp. It only restores hair in the crown of you scalp.

Regaine is probably the most popular treatment on the market for hair loss and works best when used in conjunction with propecia. Rogaine has the active ingredient monoxidil and was initially intended to treat high blood pressure. You can imagine the surprise when men who were taking Rogaine to treat their high blood pressure noticed that they were growing hair where the previously had none. Originally Rogaine was called Loniten and only when more tests were carried out to see if it really could be used as a possible male hair loss treatment did they rebrand it as Rogaine. As soon as it made its way over to Europe it was renamed Regain. Rogaine isn't like propecia where you have to go through the official channels in order to get some. You can buy it at your local pharmacy and even online. I urge you to be wary of buying online. A lot of companies can sell what they claim is Rogaine or at least is as good as but in the end you could be wasting your money. The problem with buying online is that it's hard to police. People can set up a site, get a load of sales before closing the site down and you've got nowhere to turn should your product turns out to be fake. If you don't think that Rogaine is going to be enough for your hair loss then you don't have to worry. There are plenty of other hair loss treatments available. Rogaine may not be enough even if used in conjunction with propecia but that doesn't mean that you have to go through life without your hair.